161 related articles for article (PubMed ID: 15622331)
21. Outcomes of Malaysian patients with advanced lung adenocarcinoma and unknown epidermal growth factor receptor mutation status treated with gefitinib.
Liam CK; Ruthranesan M; Lee CH; Pang YK; Chua KT; Lim BK
Asia Pac J Clin Oncol; 2012 Sep; 8(3):267-74. PubMed ID: 22897510
[TBL] [Abstract][Full Text] [Related]
22. Targeted therapies: Tyrosine-kinase inhibitors--new standard for NSCLC therapy.
Saijo N
Nat Rev Clin Oncol; 2010 Nov; 7(11):618-9. PubMed ID: 20981125
[No Abstract] [Full Text] [Related]
23. PPARγ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARγ/PTEN/Akt pathway.
Ni J; Zhou LL; Ding L; Zhao X; Cao H; Fan F; Li H; Lou R; Du Y; Dong S; Liu S; Wang Z; Ma R; Wu J; Feng J
Exp Cell Res; 2017 Dec; 361(2):246-256. PubMed ID: 29080795
[TBL] [Abstract][Full Text] [Related]
24. Adenocarcinoma of the lung with rare insertion mutation in EGFR exon 19 that had partial response to gefitinib: a case report.
Kozlov V; Karpov I; Kovalenko S; Shamanin V
Exp Oncol; 2017 Jul; 39(2):155-156. PubMed ID: 29483495
[TBL] [Abstract][Full Text] [Related]
25. Gefitinib for non-small cell lung cancer patients with liver cirrhosis.
Kim YH; Mio T; Mishima M
Intern Med; 2009; 48(18):1677-9. PubMed ID: 19755773
[TBL] [Abstract][Full Text] [Related]
26. Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancer.
Cho D; Kocher O; Lee JC; Tenen DG; Meyerson ML; Janne PA; Halmos B
J Clin Oncol; 2005 Jan; 23(1):235-7. PubMed ID: 15625379
[No Abstract] [Full Text] [Related]
27. Surgical resection of locally advanced epidermal growth factor receptor (EGFR) mutated lung adenocarcinoma after gefitinib and review of the literature.
Marech I; Vacca A; Gnoni A; Silvestris N; Lorusso V
Tumori; 2013; 99(5):e241-4. PubMed ID: 24362878
[TBL] [Abstract][Full Text] [Related]
28. Epidermal growth factor receptor mutations in synchronous recurrent lung cancer in an 82-year-old woman. A case story.
Kristiansen C; Olsen KE; Hansen NC; Hansen KH; Hansen O
Acta Oncol; 2012 Sep; 51(7):948-9. PubMed ID: 22471746
[No Abstract] [Full Text] [Related]
29. Pneumonectomy after response to gefitinib treatment for lung adenocarcinoma.
Funakoshi Y; Takeuchi Y; Maeda H
Asian Cardiovasc Thorac Ann; 2013 Aug; 21(4):482-4. PubMed ID: 24570539
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung.
de Lima Lopes G; Segel JE; Tan DS; Do YK; Mok T; Finkelstein EA
Cancer; 2012 Feb; 118(4):1032-9. PubMed ID: 21792863
[TBL] [Abstract][Full Text] [Related]
31. Molecular selection trumps clinical selection.
Shepherd FA
J Clin Oncol; 2011 Jul; 29(21):2843-4. PubMed ID: 21670452
[No Abstract] [Full Text] [Related]
32. Gefitinib is an additional prognostic factor in metastatic lung adenocarcinoma.
Kagohashi K; Satoh H; Ohtsuka M
Respirology; 2006 Nov; 11(6):835; author reply 836. PubMed ID: 17052320
[No Abstract] [Full Text] [Related]
33. ZD1839 (Iressa) in non-small cell lung cancer.
Herbst RS; Kies MS
Oncologist; 2002; 7 Suppl 4():9-15. PubMed ID: 12202783
[TBL] [Abstract][Full Text] [Related]
34. Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study.
Boldrini L; Alì G; Gisfredi S; Ursino S; Baldini E; Melfi F; Lucchi M; Comin CE; Maddau C; Tibaldi C; Camacci T; Servadio A; Mussi A; Fontanini G
Oncol Rep; 2009 Oct; 22(4):683-91. PubMed ID: 19724844
[TBL] [Abstract][Full Text] [Related]
35. Successful treatment of lung cancer with gefitinib and EGFR mutation status determination using EBUS-TBNA samples in an extremely old patient.
Nishimura H; Nakajima T; Itakura M; Shingyoji M; Iizasa T; Kimura H
Intern Med; 2009; 48(21):1905-7. PubMed ID: 19881244
[TBL] [Abstract][Full Text] [Related]
36. Gefitinib: a new agent in palliative care.
Prommer E
Am J Hosp Palliat Care; 2004; 21(3):222-7. PubMed ID: 15188923
[TBL] [Abstract][Full Text] [Related]
37. Gefitinib (Iressa): a novel treatment for non-small cell lung cancer.
Vansteenkiste J
Expert Rev Anticancer Ther; 2004 Feb; 4(1):5-17. PubMed ID: 14748652
[TBL] [Abstract][Full Text] [Related]
38. [Efficacy of low-dose erlotinib against gefitinib-induced hepatotoxicity in a patient with lung adenocarcinoma harboring EGFR mutations].
Kitade H; Yamada T; Igarashi S; Hokkoku K; Mori M; Shintaku K; Sagawa M; Nakai M; Yano S
Gan To Kagaku Ryoho; 2013 Jan; 40(1):79-81. PubMed ID: 23306923
[TBL] [Abstract][Full Text] [Related]
39. Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China.
Wu YL; Chu DT; Han B; Liu X; Zhang L; Zhou C; Liao M; Mok T; Jiang H; Duffield E; Fukuoka M
Asia Pac J Clin Oncol; 2012 Sep; 8(3):232-43. PubMed ID: 22897752
[TBL] [Abstract][Full Text] [Related]
40. Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene.
Chiari R; Duranti S; Ludovini V; Bellezza G; Pireddu A; Minotti V; Bennati C; Crinò L
J Clin Oncol; 2014 Mar; 32(9):e30-2. PubMed ID: 24419120
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
